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INTRODUCTION
Burkitt’s lymphoma (BL) is a rapidly growing 
childhood tumour characterised by mature small 
non-cleaved B-cells and commonly presents as a 
jaw or abdominal swelling in tropical Africa (1, 2). 
In resource poor countries like Kenya, diagnosis is 
purely made on microscopy thus making it difficult to 
differentiate variants of BL and other non-Hodgkin’s 
lymphoma accurately. About 40% of childhood cancer 
admissions at a national referral hospital paediatric 
facility are due to non- Hodgkin’s lymphoma. 
Ninety per cent are clinically categorised as BL 
and a common protocol is used for treatment (3). 
Treatment of non-Hodgkin’s lymphoma has evolved 
over the years from monotherapy to highly effective 
short intensive combination regimens. A standard 
structured childhood cancer treatment protocol 
was first introduced in Kenya in the mid seventies. 
It was last revised in the early eighties when the 
best practice world over was to treat using an acute 
lymphoblastic leukemia (ALL) - like regimen that 
stretched over a two year period. In keeping with 
local practice, modification of the short intensive dose 
LBM-89 protocol by Patte et al (4) was introduced in 
the year 2002 without assessment of its effectiveness 
and toxicity. There are no good quality clinical trials 
from developing countries to realistically inform 
local treatment of BL and non-Hodgkin’s disease 
(5). A major limitation to the implementation of 
modern treatments in sub-Sahara Africa have been the 
enhancement of bone marrow toxicity and inability 
to provide necessary supportive care (6). This study 
was undertaken to review and compare effectiveness 
and toxicity of the short, intensive and the longer 
less intensive, standard ALL-like chemotherapy 
regimens. Study findings would assist clinicians to 
better understand the outcome of their care and hence 
inform treatment choice. 
MATERIALS AND METHODS
The study was undertaken between January 2003 
and June 2005 at the Kenyatta National Hospital 
(KNH), a national referral and medical teaching 
hospital in Kenya. Source of information was medical 
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ABSTRACT 
Background: Effectiveness and toxicity of childhood cancer treatments have never been 
evaluated in Kenya since introduction of structured care in the early seventies. 
Objective:To evaluate effectiveness and toxicity of two treatment protocols for Non-
Hodgkin’s lymphoma (NHL). 
Design: Historical cohort study using medical records. 
Setting: Kenyatta National Hospital, a tertiary care and medical teaching hospital. 
Subjects: Children ≤ 15 years with diagnosis of non-Hodgkin’s Lymphoma. 
Main outcome measures: Primary outcomes were median survival, event free survival 
and toxicity. 
Results: Out of 101 records, only 26 (25.7%) met inclusion criteria. Baseline characteristics 
were similar in the two treatment arms. Median survival was 0.75 months (95%CI=0.54-
0.96) and 1.0 months (95% CI=0.29-1.71) for short and long arm groups. There was no 
difference in event free survival and haematological toxicity. 
Conclusion: No clear difference in effectiveness and toxicity between the intensive-
short and the less aggressive long course chemotherapy regimens was evident. Though 
lack of difference may be attributed to the small sample size, suboptimal supportive 
care for intensive treatment would increase risk of toxic deaths. As the short course 
protocol did not demonstrate obvious deterioration of median and event free survival, 
a strong case may be made for a randomised clinical trial within a context of improved 
supportive care. 
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records of in-patients. An approximately equal 
number of children with non-Hodgkin’s lymphoma 
are admitted to a 30 bed children cancer ward and 
general paediatric, ear  nose and throat and eye 
wards. Though cancer treatment is directed by the 
same team of clinicians, quality of nursing care and 
availability of medical supplies is better in the cancer 
ward. Unlike in the general paediatric wards where 
bed sharing is the norm, the latter does not admit 
beyond official capacity. Records for patients treated 
for non-Hodgkin’s lymphoma were identified from 
the hospital medical records department which 
maintains a fairly up to date electronic data base by 
diagnosis using ICD 10 classification. Majority was 
deemed to correspond to C83 category of “diffuse 
non-Hodgkin’s lymphoma”. Coded data extraction 
forms were used to collect, among other, information 
on age, sex, nature of clinical presentation, diagnostic 
work up, cancer treatment, inpatient morbidity, 
remission status, recurrence and death. Records of 
all children below the age of 15 years admitted with 
either fine needle aspirate or histological diagnosis 
of BL or non-Hodgkin’s lymphoma over the study 
period were eligible for inclusion. Those who died 
before completion of induction and ones on protocols 
other than the specified two were excluded. As 
routine screening for HIV was not practiced, no 
efforts were made to determine serological status of 
the patients. 
 Treatment toxicity was defined as (i) need for 
parenteral antibiotics, (ii) platelet transfusion, and (iii) 
packed blood cells, as surrogates for severe sepsis, 
severe thrombocytopenia and anaemia respectively. 
Requested products needed not be available or 
transfused for the incident to be included. As a policy, 
all children with two or more recordings of fever 
are commenced on parenteral antibiotics except for 
those with blood smear positive slides for malaria. 
Platelet transfusion is indicated for blood levels  below 
20x109/L or overt bleeding at higher levels and packed 
cell transfusion for haemoglobin level below 9.5g/dl. 
Haemogram reports were also reviewed. Moderate to 
severe neutropenia was defined as neutrophil count 
below 750/mm3. Frequency of toxic episodes was 
quantified from zero to three and above. 
The two treatment protocols under examination 
were: 
(i) Standard protocol: Induction - cyclophosphamide 
600mg/M2 weekly x 4 weeks, adriamycin 40mg/
M2 weekly, vincristine 1.5 mg/M2 weekly x 4 
and prednisone 40mg/M2 daily for 4 weeks. 
Consolidation (2 courses 7-10 days apart) 
- adriamycin 50mg/M2 in first course only, 
cyclophosphamide 1200mg/M2 and cytosine 
arabinoside 1 00mg/M2 daily x 4 days. Five doses of 
weekly intra-thecal methotrexate alternating with 
cytosine arabinoside given for central nervous 
system prophylaxis. Maintenance (monthly for 
24 months) - oral prednisone 40mg/M2 daily x 
1 week, oral methotrexate 15 mg/M2 weekly, 
monthly vincristine 1.5mg/M2 and 75mg/M2 
oral 6-mercaptopurine daily. Intensification with 
addition of adriamycin and cyclophosphamide 
was provided thrice monthly. 
(ii) Short intensified protocol: Induction - similar to 
above but adriamycin given in week 1 and 3 only. 
Dose of iv cyclophosphamide reduced to 500mg/
M2 weekly and IT cytosar weekly. Intensification 
- (i) adriamycin 50mg/M2, iv cyclophosphamide 
2gm/M2, IT methotrexate. (ii) Adriamycin 50mg/
M2, vincristine 2mg/M2, iv. Cytosine arabinoside 
100mg/M2 daily x 4 days and IT methotrexate. 
(iii) vincristine 2mg/M2, Iv cytosine arabinoside 
100mg/M2 daily x 4 days, iv cyclophosphamide 
1gm/M2 and IT methotrexate. (iv) adriamycin 
50mg/M2, vincristine 2mg/M2, iv cytosine 
arabinoside 100mg/M2 daily x 4 days, and IT 
methotrexate. The four course cycle is repeated 
once to complete therapy. 
 Availability of chemotherapy was arbitrarily 
scored as good if 50% or more of prescribed drugs 
were administered. 
 Baseline demographic and clinical parameters 
were compared for the standard and short treatment 
course groups. Kaplan-Meier and Chi-square 
methods were used in analysis to determine median 
survival, event free survival (EFS) and rates of 
toxicity as the main outcomes. Institutional ethical 
clearance was obtained from the KNH Scientific and 
Ethics Committee and confidentiality of information 
guaranteed. 
RESULTS
Out of 101 records retrieved, only 26 (25.7%) were 
considered suitable for further analysis. Reasons 
for exclusion included use of different protocol, 
coding error or age above 15 years. Another large. 
number (26.7%) died or absconded from hospital 
before completion of induction while 16.8% were 
diagnosed before the study date of January 2003. 
Sixteen (15.8%) records were reported as missing. 
Records were generally deficient in details on disease 
status during follow up period. Majority (77.8%) of 
those who died before completion of induction were 
in general wards. There were longer diagnostic and 
treatment delays in the general wards. 
 Table 1 shows baseline characteristics of the 
study cases. Follow up period ranged between one 
and 18 months with a median of seven months from 
time of diagnosis. In the short course regimen, 58.3% 
presented with jaw tumours compared to 35.7% 
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on the standard course treatment (p>0.05). Nine 
patients had jaw presentation (33.3%) and seven 
(28.6%) abdominal masses at diagnosis (p=0.22). 
Diagnosis was confirmed by FNA in 78% and 
by histology in 47.3% of the patients. There was 
no significant difference in baseline clinical and 
laboratory characteristics between the two groups. 
Abnormal lymphoid cells in the CSF at presentation 
occurred in half of the patients on both protocols 
but reconciliation with clinical features was not 
possible due to inadequacy of information. Rating 
of availability of drugs was considered good in 
58.3% on the short course regimen and 57.1% in the 
standard arm (p=0.63). 
Table 1
Baseline characteristics
Sex 
  Male  65.4% 
  Female  34.6%
Follow-up 
  Range 1-18 months 
  Median 7 months
Presentation * 
  Jaw 46.2% 
  Abdomen  30.8%
  Abnormal CSF 38.5% 
  FNA diagnosis  78.9%
  Histology  47.3% 
  Radiotherapy 15%
Rx Regimen 
  Short course (12) 46.2% 
  > 50% drugs  58.3% 
  Long course (14)  53.8% 
  > 50% drugs 57.1%
  Incomplete induction 69.2%
*Site of presentation SC/LC p=0.22 
Treatment toxicity profile of the two protocols is shown 
in Table 2. Over all, packed red blood cells transfusion 
was requested for 19.2%, platelet transfusion for 3.8% 
and intravenous antibiotic treatment for 53.8% of 
the patients. All those put on parenteral antibiotics 
had moderate to severe neutropenia. Frequency 
of antibiotic prescription was similar in the two 
treatment groups (p= 0.91). There was no statistical 
difference in packed cells and platelet requirements 
between the groups. 
Table 2
Treatment toxicity
 Short course Long course 
Packed cells request 33.3% 7.1%
Platelets request 8.3% 0
Iv antibiotics use 58.3% 50%
PMN<750 50% 57.1%
(p>0.05) 
A similar proportion was alive and disease-free at the 
time of last hospital review in both groups; 58.3% in 
short treatment arm and 50% in standard arm (Table 
3). Median survival was 0.75 year (95% CI=0.54-0.96) 
for short treatment and 1.00 year (0.29-1.71) for 
standard arm. There was no difference in Event Free 
Survival (probability of survival = 0.2) between the 
two groups (Figure 1). 
Table 3
Main treatment outcome
 Short  Long  Total
 course course  
 No. (%) No. (%) No. (%)
Alive disease free  7  58.3 7  50 14 53.8
Died or relapsed  5  41.7 7  50 12 46.2
Total  12 100 14 100 26 100
Figure 1
Survival functions
DISCUSSION
Non-Hodgkin’s lymphoma is the most common 
childhood malignancy in Kenya, with Burkitt’s 
lymphoma being the leading clinical sub-type. 
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Diagnosis is often made on basis of clinical 
presentation supported by either fine needle 
aspirate cytology or tissue microscopy. Since cyto-
histochemistry, immunophenotype and cytogenetic 
laboratory support are not available, sub-classification 
is not possible. Patients are treated using one of the two 
protocols as determined by the primary clinician. The 
protocols have been in place at the Kenyatta National 
Hospital since 2002 when the more intensive but 
shorter treatment regimen, a modification of the LMB-
89 protocol, was introduced (4). The older treatment 
protocol still in use today, with minor modifications 
was first introduced in the late seventies. An overlap 
of the two offered a unique opportunity to compare 
performance. Adequate amount of chemotherapy 
was received by 58.3% in the intensive treatment 
arm and 57.1% in the long treatment group. Even 
though many records did not indicate what the 
disease stage was at admission, presence of overt 
central nervous system disease (31.0%), abnormal 
cerebral spinal fluid (38.7%) and bone marrow disease 
(7.1%) confirmed that a large proportion presented 
in advanced disease. Meremikwu et al (7) in a review 
of childhood cancer hospital records in Nigeria 
observed that only 51.2% received what was defined 
as “adequate chemotherapy” while 20% received 
none at all. Similar to the situation in Kenya, they 
found availability of diagnostic services and drugs 
in public hospitals to be erratic and only affordable 
to the few with ability to buy. 
 In 1991, Patte et al (4) demonstrated that duration 
of treatment for B-cell lymphoma could be shortened 
without compromising outcome but also emphasized 
the need for good supportive care. Spreafico et al (8) 
later reported an 81% event free survival in children 
treated on a 45-day methotrexate, doxorubicin, 
cytosine arabinoside, cyclophosphamide and cis-
platin intensified regimen. Etoposide and ifosfamide 
were added in treatment of those with more advanced 
disease. Their experience was in keeping with that 
of Kouroukis et al (9) who found haematological 
toxicity to be a common limitation to delivery of 
chemotherapy in a timely manner. Hesseling et al 
(10,11), in two separate studies, reported a modest 
increase in both effectiveness and toxicity from 
intensification of Burkitt’s lymphoma treatment 
in Malawi, a setting with suboptimal quality of 
supportive care. Overall, outcomes improved despite 
increase in toxicity. 
 Preference for an older ALL-like chemotherapy 
protocol has continued in Kenya because of concerns 
that treatment intensification would result in 
unacceptable toxicity and mortality given gross 
inadequacy of supportive care in public hospitals. 
Local anecdotal experience of the author with a 
modified intensive protocol in private hospitals 
where supportive care is better demonstrated 
superior treatment outcomes. This prompted the 
introduction of a less aggressive treatment protocol 
at the KNH. Observation in this study that only 22.2% 
died before completion of induction treatment in the 
children cancer ward, which has better supportive 
care compared to 53.8% in the general ward, may 
be a reflection of importance of supportive care. The 
increase would not be attributable to tendency for 
more patients in the cancer ward to be put on the less 
intensive ALL-like protocol since the induction phases 
of the two study regimens are almost identical. 
 Granted that only twenty six  records were 
suitable for evaluation, a larger sample size would 
be needed to determine if observed lack of statistical 
difference in frequency of moderate to severe 
neutropenia, use of parenteral antibiotics, packed red 
blood cells and platelet concentrates is indeed real. 
HIV status was not controlled for in the analysis and 
difference in prevalence between the groups could 
have affected the findings as HIV has been reported 
to be associated with an increase in toxicity and 
frequency of infections (12,13). 
 While an increase in toxicity would be expected 
with use of aggressive regimens, measures to contain 
toxicity should be instituted rather than discount its 
potential benefits. In their recent publication in a similar 
setting in Africa, Harif et al (14) observed a progressive 
increase in overall survival of B-cell lymphoma 
children on an LMB modified protocol over a three 
year period from 54% to 73% following improvements 
in supportive care. As would be expected, most early 
deaths in their study were therapy related. While Orem 
et al (13) only expressed the need for improvement of 
supportive care to help cope with more aggressive 
modern treatments in Africa, Meremikwu et al (7) 
went further to propose a regional initiative that 
would ensure chemotherapy and supportive care 
was available to majority of children with Burkitt’s 
lymphoma in the African region. 
CONCLUSION
Overall outcome of non-Hodgkin’s lymphoma 
treatment at KNH remains poor and many patients 
die during early stages of treatment. There was 
no clear difference in effectiveness and toxicity 
between the modified short and the long course 
chemotherapy treatment regimens used for treatment 
of non-Hodgkin’s lymphoma in Kenya. Rapid patient 
work up for early commencement of chemotherapy 
and improvement of supportive care may reduce 
mortality and loss to follow up during early 
treatment. A randomized controlled clinical trial is 
needed to determine if a short intensive regimen will 
provide better outcomes when supported by more 
efficient pre-treatment work up and improvement 
of supportive care. 
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